跳至主要内容
临床试验/NCT04892680
NCT04892680终止不适用

Enhancing Cardiometabolic Care Study

Omada Health, Inc.2 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2021年3月4日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
27
试验地点
2
主要终点
Change in HbA1c at 6 months from baseline

研究概览

简要总结

The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.

详细描述

Approximately 45% of patients with type 2 diabetes do not achieve adequate glycemic control (A1C < 7%). When diabetes is uncontrolled, complications develop that threaten health and endanger life. This study will make an effort to address this growing health challenge and to reduce the burden of diabetes in this population. More broadly, this study will have important implications and benefits for the growing diabetes population in the U.S. Study results will inform future interventions to reduce diabetes and improve outcomes. A better understanding of the efficacy of a digital chronic disease self-management program will directly benefit the participants of the program but, in the future, has the potential to more broadly benefit this population throughout the nation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults at least 18 years of age and less than 65 years of age
  • Overweight (BMI ≥ 25 kg/m2, or BMI ≥ 23 kg/m2 if of Asian descent)
  • Uncontrolled type 2 diabetes (HbA1C ≥7.5% and ≤12%)
  • Diagnosed with type 2 diabetes at least 6 months ago, but not more than 10 years ago
  • Has a compatible smartphone running either Android Operating System 5.0 or higher, or iPhone 7 or later, running iOS 11 or higher.
  • Willing to set up an online account
  • An email address in regular use
  • Ambulatory (e.g., living at home and not in a skilled nursing facility)
  • Able to speak, understand, and read English

排除标准

  • A diagnosis of Type 1 diabetes
  • Currently pregnant or postpartum (within 4 weeks)
  • Currently using a continuous glucose monitor to manage diabetes
  • Known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin
  • Skin lesions, scarring, redness, infection or edema at the continuous glucose monitor application sites (upper arm) that could interfere with sensor placement or the accuracy of interstitial glucose measurements
  • An active eating disorder such as anorexia or bulimia (not including binge-eating disorder) for which he/she has received treatment in the past 12 months
  • Alcohol or substance abuse that impairs ability to participate in the program
  • Unable to engage in physical activity for more than 2 months over the next 6 months (i.e. due to injury or recent or planned surgery)
  • Any of the following in the past 3 months AND are not medically cleared by your physician to exercise: Transient ischemic attack or stroke; Heart attack (myocardial infarction); Hospitalization for congestive heart failure; Cardiac surgery (such as coronary artery bypass grafting (CABG), coronary artery stenting); Bariatric/gastric bypass surgery
  • Received a solid Organ Transplant (kidney, liver, etc.) within the past 6 months
  • Recent (within the last 6 months) or planned cancer treatment (chemotherapy, radiation, bone marrow transplant, cancer-related surgery - not including hormonal chemotherapy, such as tamoxifen).
  • On dialysis treatment
  • Taking steroids or prednisone (high doses) or getting cortisone injection
  • Stage 4-5 Chronic Kidney Disease
  • Class 3-4 Congestive Heart Failure
  • Participation in diabetes education in the last 30 days

结局指标

主要结局

Change in HbA1c at 6 months from baseline

时间窗: Baseline, 6 months

Non-fasting venous blood sample

次要结局

  • Change in weight at 6 months from baseline(Baseline, 6 months)
  • Change in medication adherence at 6 months from baseline(Baseline, 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验